NEW YORK (TheStreet) -- CHANGE IN RATINGS
initiated at Oppenheimer with an Outperform rating and $15 price target. Robust backlog, favorable industry fundamentals, and solid execution.
Abercrombie & Fitch
upgraded at BMO Capital to Outperform from Market Perform at BMO Capital.
upgraded at Jefferies to Buy from Hold on increased expectations for apixaban and ipilimumab, and a low risk of losing US exclusivity early for Abilify. Price target increased to $30 from $28.80.
upgraded at Robert W. Baird to Outperform from Neutral. Credit trends are improving and balance sheet trends are promising. $42 price target.
China Power Equipment
initiated at Rodman & Renshaw with a Market Outperform and $6 price target. The company is an emerging market leader in improving power grid efficiency in China.
initiated at Morgan Joseph with a Buy rating and $25 price target. Large OEMS have announced increased production rates on large commercial aircraft in response to customer demand.
upgraded at Wells Fargo to Outperform from Market Perform at Wells Fargo.
upgraded at Wunderlich to Buy from Hold as earnings power from Harry Allen power plant in 2012 makes valuation attractive. $14.50 price target.
downgraded at Piper Jaffray. VFC downgraded to Neutral from Overweight at Piper Jaffray
STOCK COMMENTS / EPS CHANGES
price target lowered at Merriam to $12-$15 ahead of its analyst day on Sept 16. Expect management to reaffirm guidance. Reiterate Buy rating.
estimates changed at Citi. HS 2010 EPS estimate trimmed to $3.05, 2011 raised to $3.80. Acquisition of Bravo Health is risky. Maintain Hold rating and $19 price target.
target, estimates lifted at Credit Suisse. IVZ 3Q10 & 2011 EPS estimates increased to $0.32 and $1.63, respectively. Strong flow estimate for 3Q10 and potential for share repurchases. Reiterate Outperform rating.
estimate raised at Barclays. JOYG 2010 EPS estimate increased to $4.00 from $3.90 on more optimistic 3Q10 earnings. Long-term backlog remains attractive. Maintain Overweight rating and $70 price target.
target, estimate cut at Credit Suisse. STI 3Q10 EPS estimate declined to -$0.26 from -$0.18 on higher provisions, net charge-offs. Price target lowered to $29 from $31. Maintain Outperform rating.
price target cut at Citi. WINN price target lowered to $11 from $16 on 4Q10 EPS miss. Same store sales worse than expected but gross margin preserved. Maintain Buy rating.
This article was written by a staff member of TheStreet.